Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
DXLE7F
|
||||
| Drug Name |
N-{4-[5-(2-Thienyl)-1,2,4-oxadiazol-3-yl]phenylcarbamoyl}-leucyl-glycine-nitrile
|
||||
| Synonyms |
CHEMBL1651358
|
||||
| Indication | Discovery agent | Investigative | [1587926] | ||
| Formula |
C21H22N6O3S
|
||||
| Canonical SMILES |
CC(C)C[C@H](NC(=O)Nc1ccc(cc1)c2noc(n2)c3cccs3)C(=O)NCC#N
|
||||
| InChI |
InChI=1S/C21H22N6O3S/c1-13(2)12-16(19(28)23-10-9-22)25-21(29)24-15-7-5-14(6-8-15)18-26-20(30-27-18)17-4-3-11-31-17/h3-8,11,13,16H,10,12H2,1-2H3,(H,23,28)(H2,24,25,29)/t16-/m0/s1
|
||||
| InChIKey |
BUKNXMUGAFKJMC-INIZCTEOSA-N
|
||||
| Target and Pathway | |||||
| Target(s) | Cathepsin K | Target Info | [1587926] | ||
| Cathepsin L | Target Info | [1587926] | |||
| Reactome | Collagen degradation | ||||
| Degradation of the extracellular matrix | |||||
| Activation of Matrix Metalloproteinases | |||||
| Trafficking and processing of endosomal TLR | |||||
| MHC class II antigen presentationR-HSA-1236977:Endosomal/Vacuolar pathway | |||||
| Assembly of collagen fibrils and other multimeric structures | |||||
| MHC class II antigen presentation | |||||
| References | |||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.